For secondary prevention, we recommend using at least a moderate-dose statin.* Strong for 12. For secondary prevention in higher risk patients** who are willing to intensify treatment, we suggest offering high-dose statins for reducing non-fatal cardiovascular events after discussion of the risk of high-dose statins and an exploration of the patient s values and preferences. Weak for 13. For secondary prevention in higher risk patients** who are willing to intensify treatment, we suggest adding ezetimibe to either moderate- or high-dose statins for reducing non-fatal cardiovascular events following a discussion of the risks, additional benefits, and an exploration of the patient s values and preferences. Weak for 14. For secondary prevention in higher risk patients** who are willing to intensify treatment, we suggest offering a PCSK9 inhibitor in addition to a maximally tolerated statin dose with ezetimibe for reducing non-fatal cardiovascular events following a discussion of their uncertain long-term safety, additional benefits, and an exploration of the patient s values and preferences. Weak for c. Other Medications, Supplements, and Nutraceuticals 15. For primary or secondary prevention, we recommend against using niacin (i.e., supplements or prescriptions). Strong against 16. For primary or secondary prevention, we suggest against adding fibrates to statins. Weak against 17. There is insufficient evidence to recommend for or against using bempedoic acid with or without statins for either primary or secondary prevention. Neither for nor against VA/DoD CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction Provider Summary Topic Sub- topic # Recommendation Strengtha Pharmacotherapy, Supplements, and Nutraceuticals (cont.) c. Other Medications, Supplements, and Nutraceuticals (cont.) 18. For primary prevention, there is insufficient evidence to recommend for or against icosapent ethyl in patients on statin therapy with persistently elevated fasting triglycerides. Neither for nor against 19. 